Pharvaris N.V. 20-F Filing Summary
Business Context and Reporting Period
Company: Pharvaris N.V.
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Pharvaris is a late-stage biopharmaceutical company developing oral therapies for bradykinin-mediated diseases, primarily Hereditary Angioedema (HAE). The company has no commercial products and generates no revenue. Its pipeline focuses on two formulations of deucrictibant: an immediate-release (IR) capsule for on-demand treatment and an extended-release (XR) tablet for prophylaxis. Both candidates are currently in pivotal Phase 3 clinical trials.
Key Financial Metrics
| Metric (in EUR) | 2024 | 2023 |
|---|---|---|
| Revenue | 0 | 0 |
| Net Loss | (134.2 million) | (100.9 million) |
| Operating Expenses | (145.7 million) | (96.9 million) |
| Research & Development Expenses | (98.6 million) | (65.6 million) |
| General & Administrative Expenses | (47.1 million) | (31.3 million) |
| Finance Income (Net) | 13.3 million | (2.9 million) |
| Cash and Cash Equivalents (Year End) | 280.7 million | 391.2 million |
| Net Cash Used in Operating Activities | (120.1 million) | (93.0 million) |
| Outstanding Shares (Dec 31, 2024) | 54,379,491 | 52,290,212 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 33% (€33.3 million) to €134.2 million, driven by a 50% increase in total operating expenses.
- R&D Expense Surge: R&D expenses rose by 50% (€33.0 million) to €98.6 million. This was primarily due to an 82% increase in clinical expenses (€25.2 million) associated with the initiation of Phase 3 trials (RAPIDe-3 and CHAPTER-3) and open-label extension studies.
- Finance Income Turnaround: Finance income swung from a €2.9 million expense in 2023 to a €13.3 million income in 2024. This was driven by €7.9 million in unrealized foreign exchange gains (due to USD strengthening against EUR) and increased interest income (€5.5 million vs €0.2 million).
- Cash Position: Cash and cash equivalents decreased by €110.5 million to €280.7 million, reflecting the burn rate from expanded clinical activities, despite the foreign exchange gains.
Guidance, Outlook, and Risks
- Clinical Milestones:
- RAPIDe-3 (On-Demand): Initiated March 2024; enrolling ~120 participants. Topline data anticipated in Q1 2026.
- CHAPTER-3 (Prophylaxis): Initiated December 2024; enrolling ~81 participants. Topline data anticipated in H2 2026.
- Liquidity Outlook: Management believes current cash balances (€280.7 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring significant losses until commercialization.
- Key Risks:
- Regulatory History: The FDA previously placed clinical holds on deucrictibant in 2022 due to nonclinical findings. These holds were lifted in June 2023 (on-demand) and January 2024 (prophylaxis) following a 26-week rodent toxicology study. Future regulatory delays remain a risk.
- Capital Requirements: The company has no revenue and relies on equity financing. Failure to raise additional capital could force delays or termination of development programs.
- Geopolitical Factors: Clinical trials in Germany, Poland, Bulgaria, and Israel could be impacted by geopolitical instability (Russia-Ukraine conflict, Israel-Hamas war).
- Intellectual Property: Core IP is licensed from BRAIN Biotech AG. Failure to meet milestone payments could result in loss of rights.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the €280.7 million cash balance against the projected burn rate for the upcoming Phase 3 trials and potential need for additional financing before 2026.
- Clinical Trial Enrollment: Monitor enrollment progress for RAPIDe-3 and CHAPTER-3, particularly given the geopolitical risks in trial locations.
- Regulatory Status: Confirm continued clearance of FDA clinical holds and alignment on Phase 3 protocols with the FDA and EMA.
- Foreign Exchange Exposure: Assess the impact of EUR/USD fluctuations on future financial reporting, given the significant unrealized FX gains in 2024.
- Contractual Obligations: Review the €109.9 million in R&D commitments and the remaining €9.0 million in potential milestone payments to BRAIN Biotech AG.